Published in Blood on April 01, 1997
Role of allogeneic transplantation in multiple myeloma in the era of new drugs. Mediterr J Hematol Infect Dis (2010) 0.76
Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer. Eur J Cancer (2011) 1.62
Imatinib: a designer drug, another cutaneous complication. Clin Exp Dermatol (2009) 1.61
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol (1997) 1.48
Regression of rectal cancer with radiotherapy with or without concurrent capecitabine--optimising the timing of surgical resection. Clin Oncol (R Coll Radiol) (2008) 1.44
Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol (1994) 1.43
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) Blood (1995) 1.43
Economic evaluation of peripheral blood stem cell transplantation for lymphoma. Lancet (1992) 1.40
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
Ocular morbidity after radiotherapy of orbital and conjunctival lymphoma. Eye (Lond) (1987) 1.26
Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol (2004) 1.25
Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet (1993) 1.24
Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant (2005) 1.23
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant (2010) 1.16
Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med (1991) 1.15
Studies on the structure of the carcinoembryonic antigen. I. some deductions on the basis of chemical degradations. Immunochemistry (1974) 1.14
The use of deoxyfluoro-D-glucopyranoses and related compounds in a study of yeast hexokinase specificity. Biochem J (1972) 1.13
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol (2001) 1.10
Pregnancy associated aplastic anaemia: a report of five cases and review of current management. Br J Haematol (1989) 1.08
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant (2008) 1.08
Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia (1997) 1.07
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol (2003) 1.05
The effect of substitution at C-2 of D-glucose 6-phosphate on the rate of dehydrogenation by glucose 6-phosphate dehydrogenase (from yeast and from rat liver). Biochem J (1973) 1.01
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia (2009) 1.01
The deoxyfluoro-D-glucopyranose 6-phosphates and their effect on yeast glucose phosphate isomerase. Biochem J (1973) 1.01
Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant (1992) 1.01
Some in vivo and in vitro antitumour effects of the deoxyfluoro-D-glucopyranoses. Eur J Cancer (1973) 1.00
Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol (1995) 0.99
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia (2006) 0.98
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanisms. Br J Rheumatol (1988) 0.98
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant (2005) 0.98
Parotid metastases from carcinoma of the breast. Clin Radiol (1989) 0.97
Bone marrow transplantation: current situation, complications and prevention. J Antimicrob Chemother (1995) 0.97
Intracranial ependymoma: long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys (1992) 0.97
Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment. Leukemia (2005) 0.97
Non-Hodgkin's lymphoma of the sinonasal tract. Laryngoscope (2000) 0.96
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol (2004) 0.94
Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant (2011) 0.94
Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia (1995) 0.93
Radiation dose to the lens and cataract formation. Int J Radiat Oncol Biol Phys (1993) 0.91
Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol (1998) 0.89
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant (2001) 0.89
Acquired abnormalities of polymorphonuclear neutrophil function. Blood Rev (1990) 0.89
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol (1997) 0.89
Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer (1994) 0.88
Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant (2007) 0.88
Postoperative radiotherapy in the management of spinal cord ependymoma. J Neurosurg (1991) 0.87
Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant (1993) 0.87
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia (2010) 0.87
Primary gastric lymphoma in clinical practice 1973-1992. Gut (1995) 0.87
Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia (2004) 0.86
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy (2001) 0.86
Extramedullary haemopoiesis as a cause of mediastinal lymphadenopathy in chronic myelomonocytic leukaemia. Clin Lab Haematol (1990) 0.86
Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant (1995) 0.86
A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course. Br J Haematol (1998) 0.85
Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity. Br J Haematol (1979) 0.85
A prospective study of urinary tract infection during pelvic radiotherapy. Radiother Oncol (1989) 0.84
Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol (1999) 0.84
Role of arachidonic acid and its metabolites in the priming of NADPH oxidase in human polymorphonuclear leukocytes by peritoneal dialysis effluent. Clin Diagn Lab Immunol (1998) 0.84
Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia (2003) 0.84
Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer (1994) 0.84
The use of deoxyfluoro-D-galactopyranoses in a study of yeast galactokinase specificity. Biochem J (1974) 0.84
The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant (2000) 0.84
Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant (2007) 0.84
Effect of peritoneal dialysis effluent on superoxide anion production by polymorphonuclear neutrophils. Nephron (1993) 0.84
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia (1999) 0.84
Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant (1997) 0.84
Autoimmune hemolytic anemia caused by warm-reacting IgM-class antibodies. Immunohematology (1998) 0.84
Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol (1994) 0.84
Fluorinated carbohydrates. XI. 6-Deoxy-6-fluoro-D-glucose: an improved synthesis and the glycosyl fluoride derivatives. Carbohydr Res (1971) 0.84
MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas. J Surg Oncol (2012) 0.84
An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy (2000) 0.83
Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia (1997) 0.83
Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Haematol (1996) 0.83
Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts. Br J Cancer (2012) 0.82
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia (2012) 0.82
Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol (1996) 0.82
Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol (1994) 0.82
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol (2000) 0.82